Definitive Contract HHSN261201600014C
Award Date
9/19/16
Potential Completion Date
9/18/18
Potential Value
$300K
Federal Agency
National Cancer Institute
Awardee
Rockland Immunochemicals Inc.
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Pottstown, PA 19464, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
12
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This is a $149,970 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services, to Rockland Immunochemicals Inc. for biomedical research. The contract is a firm-fixed-price definitive contract with an ultimate completion date of April 30, 2010. Rockland Immunochemicals is a global biotechnology company that manufactures research tools and antibodies. In addition to this prime contract, Rockland has...
This is a Definitive Contract awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services (HHS), to Rockland Immunochemicals Inc., a small business manufacturer of research tools and antibodies. The $249,975 Firm Fixed Price contract is for Biomedical (Basic Research) R&D, with a period of performance ending on March 19, 2015. The contract was set aside for small businesses. In addition to this...
This is a $992,088.91 Phase II Small Business Innovation Research (SBIR) contract awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) Department of Health and Human Services (HHS), to Rockland Immunochemicals Inc., a for-profit small business corporation. The contract is for the development of a "Pharmacodynamic Assay for AKT for Use with PI3K/AKT/mTOR Inhibitors" under SBIR Topic 229. As a Phase II SBIR award, this follows a previous Phase I...
The National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services (HHS), awarded a $149,937 Small Business Innovation Research (SBIR) Phase I contract to Rockland Immunochemicals Inc., a for-profit manufacturer and S Corporation, to develop lyophilized (freeze-dried) guinea pig complement with diluent. The contract, awarded on September 30, 2010, has a completion date of August 30, 2011. Rockland Immunochemicals has also previously served as a...
This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) at the U.S. Department of Health and Human Services (HHS), to Rockland Immunochemicals Inc., a for-profit manufacturer of research tools and antibodies. The contract, valued at $5,630.00, is for custom antibody purification services. The contract does not have a set-aside designation and was awarded on January 16, 2015,...
This is a SBIR Phase I contract awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services, to Detroit R&D, Inc., a small business. The $147,520.00 fixed-price contract is for the development of glycosylation-specific research reagents, specifically antibodies and aptamers, under SBIR Topic 294. The contract was awarded on September 15, 2011 and has a completion date of December 14, 2012. Detroit R&D, Inc. is a minority-owned, for-profit,...
This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services' National Institutes of Health, to Radiomedix, Inc., a small disadvantaged business. The contract, valued at $1,994,002.00, is for the development of targeted radionuclide therapy using 212Pb-octreotate analogs for the treatment of neuroendocrine tumors. The contract was awarded on September 18, 2018 and has a completion date of...
This is a $295,782 firm fixed price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Radimmune Therapeutics, Inc., a self-certified small disadvantaged business. The contract is for a Small Business Innovation Research (SBIR) Program Phase I project focused on "RADIOIMMUNOTHERAPY OF MELANOMA WITH NOVEL LGG TO MELANIN". The contract has a completion date of September 18, 2017 and was awarded on September 19, 2016. The contract is designated as a total small...
This is a $300,000.00 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Icagen, Inc. for a Small Business Innovation Research (SBIR) Phase I project titled "SYSTEMIC TARGETED RADIONUCLIDE THERAPY FOR CANCER TREATMENT". The period of performance is from September 22, 2015 to June 21, 2016, with an ultimate completion date of September 30, 2016. This contract was not set aside for a specific business size or type. The goal of this SBIR...
This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...